Donald A. Middlebrook

Donald Middlebrook joined Nevro in January 2020 and has over 30 years of leadership experience gaining global regulatory approvals, managing significant risk clinical trials and overseeing multi-site quality assurance/compliance programs for complex Class II and III medical device companies. He served most recently as a Regulatory and Clinical Affairs Consultant for St. Jude Medical following their acquisition of Thoratec Corporation in October 2015 and then for Abbott from January 2017 when the company acquired St. Jude Medical. Prior to this, Mr. Middlebrook served as Vice President of Corporate Quality and Regulatory Affairs for Thoratec. In the span of 19 years, he was responsible for worldwide regulatory approvals, leading numerous groundbreaking clinical trials and overseeing the company’s quality system activities. Before joining Thoratec, Mr. Middlebrook was Senior Director, Global Regulatory Affairs and Quality Assurance for Chiron Vision, involved in the manufacturing of ophthalmic surgical devices. Mr. Middlebrook spent 15 years with Baxter International in several progressing positions including Vice President of Regulatory Affairs and Quality Assurance for the Cardiovascular Group (now known as Edwards Lifesciences). Mr. Middlebrook previously served as President and Chairman of the Regulatory Affairs Professional Society (RAPS) Board of Directors, was elected as a RAPS Fellow and has continued to serve on several important committees for this society. Donald Middlebrook received a B.S. in Biology from California State University, Fullerton.